Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of TQ-B3525 plus rituximab and bendamustine in relapsed/refractory B-cell non-Hodgkin lymphoma
ChiCTR2200055163Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQ-B3525, rituximab and bendamustine in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more, sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Started Aug 2020; status: recruiting.
02
Drugs
TQ-B3525rituximabbendamustine
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2200055163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055163.